» Articles » PMID: 31772737

Upper Limb Motor Improvement in Chronic Stroke After Combining Botulinum Toxin A Injection and Multi-joints Robot-assisted Therapy: a Case Report

Overview
Specialty General Medicine
Date 2019 Nov 28
PMID 31772737
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Spasticity is one of the major complications after stroke. Botulinum toxin type A (BoNT-A) injection is commonly used to manage focal spasticity. However, it is uncertain whether BoNT-A can improve activities of daily living function of paretic arm. The recovery of functions of the affected arm is also the aim of robotic upper limb (UL) therapy. The motorized exoskeleton assists the patient in a large 3D work environment by promoting movement for the UL (shoulder, elbow, wrist, hand). The combination of the BoNT-A injection and the robotic therapy might enhance functional recovery after stroke. We reported the case of a chronic stroke patient in which the injection of BoNT-A was combined with multi-joint exoskeleton training. The patient showed improvement in the motor control of the UL, supporting the feasibility of this approach.

Citing Articles

Robot-assisted upper limb therapy for personalized rehabilitation in children with cerebral palsy: a systematic review.

Cardone D, Perpetuini D, Di Nicola M, Merla A, Morone G, Ciancarelli I Front Neurol. 2025; 15():1499249.

PMID: 39835154 PMC: 11743387. DOI: 10.3389/fneur.2024.1499249.


Active, Actuated, and Assistive: a Scoping Review of Exoskeletons for the Hands and Wrists.

Galbert A, Buis A Can Prosthet Orthot J. 2024; 7(1):43827.

PMID: 39628640 PMC: 11609922. DOI: 10.33137/cpoj.v7i1.43827.


Feasibility of Adjunct Therapy with a Robotic Hand Orthosis after Botulinum Toxin Injections in Persons with Spasticity: A Pilot Study.

Ranzani R, Razzoli M, Sanson P, Song J, Galati S, Ferrarese C Toxins (Basel). 2024; 16(8).

PMID: 39195756 PMC: 11360205. DOI: 10.3390/toxins16080346.


Botulinum Toxin Type A Possibly Affects Ca3.2 Calcium Channel Subunit in Rats with Spinal Cord Injury-Induced Muscle Spasticity.

Ma K, Zhu D, Zhang C, Lv L Drug Des Devel Ther. 2020; 14:3029-3041.

PMID: 32801642 PMC: 7395704. DOI: 10.2147/DDDT.S256814.

References
1.
Wissel J, Schelosky L, Scott J, Christe W, Faiss J, Mueller J . Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010; 257(7):1067-72. PMC: 2892615. DOI: 10.1007/s00415-010-5463-1. View

2.
Devier D, Harnar J, Lopez L, Brashear A, Graham G . Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial. Toxins (Basel). 2017; 9(7). PMC: 5535163. DOI: 10.3390/toxins9070216. View

3.
Francisco G, McGuire J . Poststroke spasticity management. Stroke. 2012; 43(11):3132-6. DOI: 10.1161/STROKEAHA.111.639831. View

4.
Saita K, Morishita T, Hyakutake K, Fukuda H, Shiota E, Sankai Y . Combined therapy using botulinum toxin A and single-joint hybrid assistive limb for upper-limb disability due to spastic hemiplegia. J Neurol Sci. 2017; 373:182-187. DOI: 10.1016/j.jns.2016.12.056. View

5.
Frevert J . Xeomin: an innovative new botulinum toxin type A. Eur J Neurol. 2009; 16 Suppl 2:11-3. DOI: 10.1111/j.1468-1331.2009.02879.x. View